A recent report by WCG reveals that only 11% of surveyed pharmaceutical and biotech companies have fully integrated AI and machine learning into their clinical trial processes as of late 2024. This statistic highlights a significant disconnect between the industry's discussions about AI adoption and the actual implementation on the ground, making the 2026 Clinical Research Trends and Insights Report particularly relevant.
The report emphasizes four main themes: governance of AI and ML, readiness of sites and investigators, participant experience, and the operational challenges posed by cell and gene therapies. WCG adopts a cautious approach to AI, framing it as an emerging capability that necessitates robust governance and trust, especially in light of the FDA's draft guidance on AI in regulatory decision-making set for January 2025. This shift signifies that mere enthusiasm for AI without a solid governance framework could become a liability for companies.
On the topic of site readiness, the report notes findings from ICON's 2025 survey, which indicated that over half of the sites experienced activation delays of five months or more. WCG advocates for viewing site readiness as a continuous operational asset rather than a one-time checklist, a perspective that is crucial for sponsors managing intricate clinical portfolios. The complexities of cell and gene therapy further exacerbate these challenges, requiring specialized logistics and regulatory coordination that traditional site networks may struggle to accommodate.
The report also connects participant experience to the other themes, distinguishing between studies designed for patient convenience and those that actively incorporate patient feedback into protocol design. This distinction is vital for improving retention rates and data quality, both of which are critical for regulatory submissions. A key metric to monitor through 2026 will be whether site activation timelines improve as data-driven assessments take precedence over intuition-based selections, bridging operational efficiency and revenue for major contract research organizations (CROs).